Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials

Journal of Psychiatric Research
Taro KishiNakao Iwata


There is uncertainty about the efficacy and tolerability of blonanserin in schizophrenia. PubMed, the Cochrane Library databases, PsycINFO, and Google Scholar were searched up to September 2012. A systematic review and meta-analysis of individual patient data from randomized, controlled trials comparing blonanserin with other antipsychotics were conducted. The risk ratio (RR), 95% confidence intervals (CI), numbers-needed-to-harm (NNH), and weighted mean difference (WMD) were calculated. Four studies (total n = 1080) were identified (vs. risperidone studies [n = 508], vs. haloperidol studies [n = 572]). Comparing blonanserin with other pooled antipsychotics, there were no significant differences in the Positive and Negative Syndrome Scale (PANSS) total score (p = 0.75), PANSS positive (p = 0.41), PANSS negative (p = 0.09), and PANSS general psychopathology subscale scores (p = 0.96), and response rate (p = 0.72). However, blonanserin showed greater efficacy in PANSS negative subscale scores compared with haloperidol (WMD = -1.29, CI = -2.29 to -0.30, p = 0.01, I(2) = 0%). No significant differences were found in discontinuation rates between blonanserin and other pooled antipsychotics (due to any cause: p = 0.29, inefficacy: p ...Continue Reading


Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Jul 26, 2005·Archives of Disease in Childhood·A K Akobeng
Dec 17, 2008·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Tadashi IshibashiHiroshi Nakamura
Apr 25, 2009·The Journal of Clinical Psychiatry·John M KaneSheila Assunção-Talbott
Dec 25, 2009·CNS Drugs·Emma D Deeks, Gillian M Keating


Apr 23, 2013·European Archives of Psychiatry and Clinical Neuroscience·Taro KishiNakao Iwata
Jun 15, 2013·Neuropsychiatric Disease and Treatment·Tomomi TenjinNoboru Yamaguchi
Jun 4, 2014·Indian Journal of Psychiatry·T S Sathyanarayana Rao, Chittaranjan Andrade
May 20, 2014·Psychiatry and Clinical Neurosciences·Yuriko NinomiyaNoboru Yamaguchi
Jan 28, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Aran Min, Daeho Kim
Apr 4, 2015·Journal of Pharmacological Sciences·Satoko BabaMichiko Ono
Sep 17, 2016·Drug Development Research·Nadja P MaricCedo Miljevic
Mar 9, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Natalia I BrzozowskaJonathon C Arnold
Jul 30, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Young Sup WooWon-Myong Bahk
Dec 6, 2019·The International Journal of Neuropsychopharmacology·Konstantinos N FountoulakisHans Jurgen Moeller
Mar 4, 2017·Acta Psychiatrica Scandinavica·A G SzmulewiczS A Strejilevich

Related Concepts

Antiparkinson Agents
Double-Blind Method
Factor Construct Rating Scales (Fcrs)
Double-Blind Method

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.